HighTower Advisors LLC Sells 169 Shares of Insulet Co. (NASDAQ:PODD)

HighTower Advisors LLC trimmed its stake in shares of Insulet Co. (NASDAQ:PODD) by 5.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 2,822 shares of the medical instruments supplier’s stock after selling 169 shares during the quarter. HighTower Advisors LLC’s holdings in Insulet were worth $737,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet during the 4th quarter valued at approximately $36,000. SRS Capital Advisors Inc. raised its stake in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 56 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the period. Friedenthal Financial bought a new stake in shares of Insulet in the fourth quarter worth $57,000. Finally, Assetmark Inc. increased its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 246 shares during the period.

Insider Buying and Selling

In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on PODD. Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price target on the stock. Wells Fargo & Company lifted their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Piper Sandler upped their price target on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Raymond James reissued an “outperform” rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Citigroup raised their target price on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Price Performance

PODD opened at $258.75 on Friday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm’s fifty day moving average price is $271.69 and its two-hundred day moving average price is $258.53. The company has a market capitalization of $18.17 billion, a price-to-earnings ratio of 44.69, a P/E/G ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.